Fusion, based in
The treatment has the potential to minimize damage to healthy cells and enable access to tumours not reachable through external beam radiation.
"This acquisition combines Fusion's expertise and capabilities in radioconjugates, including our industry-leading radiopharmaceutical R&D, pipeline, manufacturing and actinium-225 supply chain, with
The company's most advanced program is a potential new treatment for patients with metastatic castration-resistant prostate cancer. It is in a Phase 2 trial.
"Between 30 and 50 per cent of patients with cancer today receive radiotherapy at some point during treatment, and the acquisition of Fusion furthers our ambition to transform this aspect of care," said
Under the terms of the deal, Fusion shareholders will receive
Fusion shares closed at
The acquisition is subject to customary closing conditions, including shareholder approval.
The deal is expected to close in the second quarter of 2024.
This report by The Canadian Press was first published
© 2024 The Canadian Press. All rights reserved., source